# Biocogniv

**Source:** https://geo.sig.ai/brands/biocogniv  
**Vertical:** Healthcare  
**Subcategory:** General  
**Tier:** Emerging  
**Website:** biocogniv.com  
**Last Updated:** 2026-04-14

## Summary

FDA Breakthrough Device-designated AI platform predicting sepsis mortality risk in emergency departments; $17.08M from Breyer Capital and YC generating $2.6M revenue at 13-person Burlington-based team.

## Company Overview

Biocogniv is a Burlington, Vermont-based clinical AI company that has developed an FDA Breakthrough Device Designation-granted platform for predicting sepsis-related mortality and ICU admission risk in emergency departments — using AI analysis of routine clinical data (vital signs, lab values, patient history) to identify patients at highest risk of deterioration hours before clinical signs become obvious to clinicians, enabling earlier intervention in one of healthcare's most time-sensitive conditions. Founded in 2019 and a Y Combinator W20 graduate, Biocogniv raised $17.08 million from Breyer Capital and YC, generating $2.6 million in revenue in 2024 with a 13-person team.

Biocogniv's algorithm analyzes the data already being collected in emergency departments — EHR data, nursing assessments, vital signs monitoring, laboratory results — to generate a continuous risk score that predicts which patients will develop sepsis-related complications requiring ICU admission within the next 6-12 hours. Unlike single-timepoint scoring systems (like SOFA or SIRS criteria), Biocogniv's model incorporates the trajectory of clinical data over time, enabling earlier detection of the subtle patterns that precede septic shock.

In 2025, Biocogniv competes in the AI clinical decision support and sepsis detection market with Sepsis-prediction tools from Epic (Deterioration Index, built into Epic EHR), IBM Watson Health (Micromedex), and Philips (IntelliVue Guardian) for sepsis risk monitoring in acute care. Sepsis kills 270,000+ Americans annually and is the leading cause of in-hospital mortality — earlier detection and intervention directly reduces mortality. The FDA Breakthrough Device Designation accelerates the regulatory pathway and signals clinical significance. Breyer Capital's investment (known for healthcare technology) provides both capital and strategic credibility. The 2025 strategy focuses on expanding hospital contracts, completing the FDA clearance process to enable broader commercial deployment, and building the EHR integration partnerships with Epic and Cerner that scale adoption beyond manual API connections.

## Frequently Asked Questions

### What is Biocogniv?
Biocogniv is an AI-powered diagnostic platform developer focused on emergency department sepsis prediction. Founded in 2019 and based in Burlington, VT, the company is a Y Combinator W20 alum that has received FDA Breakthrough Device Designation for its sepsis diagnostic tool.

### What products and services does Biocogniv offer?
Biocogniv offers an AI sepsis prediction platform that provides emergency department diagnostics, ICU admission prediction, and in-hospital mortality prediction. The company's technology is specifically designed as emergency care AI tools for healthcare facilities.

### Who are Biocogniv's target customers?
Biocogniv's target customers are emergency departments and hospitals that need advanced sepsis prediction capabilities. The platform is designed for healthcare facilities seeking to predict sepsis-related in-hospital mortality and ICU admissions at emergency department presentations.

### When was Biocogniv founded?
Biocogniv was founded in 2019. The company participated in Y Combinator's Winter 2020 (W20) batch.

### Where is Biocogniv located?
Biocogniv is headquartered in Burlington, Vermont.

### How much funding has Biocogniv raised?
Biocogniv has raised $17.08M in total funding across 5 rounds. This includes a $10.74M Seed VC round on October 19, 2023, and an earlier $6M seed round led by Breyer Capital.

### Who are Biocogniv's investors?
Biocogniv's investors include Breyer Capital, The Fund at Hula, Inflect Health, Y Combinator, Promus Ventures, and Sam Palmisano. Breyer Capital led an earlier $6M seed round.

### What are Biocogniv's key achievements and metrics?
Biocogniv achieved FDA Breakthrough Device Designation for its sepsis diagnostic tool and generated $2.6M in revenue in 2024. The company currently has a team of 13 employees.

### What technology does Biocogniv use?
Biocogniv uses AI-powered technology to predict sepsis-related outcomes in emergency department settings. The platform predicts in-hospital mortality and ICU admission at emergency department presentations.

### What are Biocogniv's recent developments?
Biocogniv's most recent funding round was a $10.74M Seed VC round completed on October 19, 2023. The company achieved $2.6M in revenue in 2024 and continues to operate with a 13-person team.

## Tags

healthtech, saas, north-america, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*